P2X7受体作为改善小鼠脓毒症诱导骨骼肌萎缩的新靶点
本研究采用盲肠结扎穿刺(CLP)建立小鼠脓毒症模型,评估腓肠肌(GP)和胫骨前肌(TA)中P2X7受体表达的时间变化,并通过P2X7基因敲除小鼠和P2X7特异性拮抗剂A-740003进行功能研究。结果显示CLP后GP和TA肌肉中P2X7受体表达呈时间依赖性上调;P2X7基因缺失显著减轻体重下降、肌肉质量减少和肌纤维萎缩,恢复握力,抑制萎缩相关基因(Myostatin、Atrogin-1和MuRF1)表达,并降低骨骼肌和血浆中IL-6、IL-18和IL-1β水平;P2X7缺失还抑制NLRP3炎症小体组分、caspase-1和gasdermin D表达,阻断焦亡信号通路。药理学抑制A-740003呈剂量依赖性减轻肌肉萎缩。结论认为P2X7受体通过激活NLRP3炎症小体和焦亡通路促进炎症和肌肉蛋白降解,参与脓毒症诱导的骨骼肌萎缩,基因或药理学抑制可显著减轻肌肉损伤和功能丧失,为P2X7作为脓毒症相关肌病潜在治疗靶点提供实验证据。
要点
- CLP诱导的脓毒症小鼠中,腓肠肌和胫骨前肌的P2X7受体表达呈时间依赖性上调。
- P2X7基因敲除显著减轻CLP小鼠体重下降、肌肉质量减少和肌纤维萎缩,并恢复握力。
- P2X7基因敲除抑制萎缩相关基因Myostatin、Atrogin-1和MuRF1表达,降低骨骼肌和血浆IL-6、IL-18、IL-1β水平。
- P2X7基因敲除抑制NLRP3炎症小体组分、caspase-1和gasdermin D表达,阻断焦亡信号通路。
- P2X7特异性拮抗剂A-740003呈剂量依赖性减轻CLP小鼠肌肉萎缩。
适用人群与场景
- 小鼠脓毒症模型(盲肠结扎穿刺法)
- 评估组织为腓肠肌和胫骨前肌
处置流程与药物剂量
- P2X7特异性拮抗剂A-740003用于CLP小鼠,呈剂量依赖性减轻肌肉萎缩(原文未写明具体剂量、给药途径和频次)。
研究设计与关键结果
- 研究类型:动物实验(小鼠脓毒症模型),采用P2X7基因敲除小鼠和P2X7特异性拮抗剂A-740003进行功能研究。
- CLP诱导的脓毒症模型中,腓肠肌和胫骨前肌的P2X7受体表达呈时间依赖性上调。
- P2X7基因缺失显著减轻体重下降、肌肉质量减少和肌纤维萎缩,恢复握力,抑制萎缩相关基因Myostatin、Atrogin-1和MuRF1表达。
- P2X7基因缺失显著降低骨骼肌和血浆中IL-6、IL-18和IL-1β水平。
- P2X7基因缺失显著抑制NLRP3炎症小体组分、caspase-1和gasdermin D表达,阻断焦亡信号通路。
- 药理学抑制A-740003呈剂量依赖性减轻肌肉萎缩。
证据类型、等级与局限
- 证据类型:动物实验(小鼠模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为P2X7受体通过激活NLRP3炎症小体和焦亡通路促进炎症和肌肉蛋白降解,参与脓毒症诱导的骨骼肌萎缩;基因或药理学抑制P2X7可显著减轻肌肉损伤和功能丧失,为P2X7作为脓毒症相关肌病潜在治疗靶点提供实验证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: Sepsis, a systemic inflammatory syndrome, frequently leads to substantial skeletal muscle loss and dysfunction, severely impairing patient prognosis. The P2X7 receptor is an adenosine triphosphate-gated cation channel implicated in inflammation and cell death. Although its role in the immune system has been extensively studied, its expression profile and pathogenic mechanism in sepsis-induced skeletal muscle atrophy remain unclear. This study aimed to investigate the functional role of the P2X7 receptor in sepsis-associated muscle injury and its potential as a therapeutic target.
METHODS: A murine sepsis model was established using cecal ligation and puncture (CLP) surgery. Temporal changes in P2X7 receptor expression in the gastrocnemius (GP) and tibialis anterior (TA) muscles were assessed. Functional studies were performed using P2X7 knockout (P2X7 - / - ) mice and the P2X7-specific antagonist A-740003. Skeletal muscle atrophy, inflammatory responses, and activation of the NLRP3 inflammasome signaling pathway were systematically evaluated through Western blotting, qPCR, hematoxylin-eosin staining, muscle fiber cross-sectional area analysis, and measurement of inflammatory cytokines.
RESULTS: In the CLP-induced sepsis model, P2X7 receptor expression in both GP and TA muscles was upregulated in a time-dependent manner. P2X7 gene deletion significantly attenuated body weight loss, muscle mass reduction, and muscle fiber atrophy, restored grip strength, and suppressed the expression of atrophy-related genes (Myostatin, Atrogin-1, and MuRF1). Moreover, it markedly reduced IL-6, IL-18, and IL-1β levels in both skeletal muscle and plasma, indicating an anti-inflammatory effect. P2X7 deficiency also significantly inhibited the expression of NLRP3 inflammasome components, caspase-1, and gasdermin D, thereby blocking the pyroptosis signaling pathway. Pharmacological inhibition with A-740003 showed dose-dependent mitigation of muscle atrophy, further supporting the therapeutic potential of targeting P2X7.
CONCLUSIONS: The P2X7 receptor contributes to sepsis-induced skeletal muscle atrophy by promoting inflammation and muscle protein degradation through activation of the NLRP3 inflammasome and pyroptosis pathways. Genetic or pharmacological inhibition of P2X7 significantly alleviates muscle damage and functional loss. These findings provide strong experimental evidence supporting P2X7 as a potential therapeutic target for sepsis-associated myopathy.
参考来源
- Liu Y, Liu Q, Xu Z, et al. P2X7 Receptor Acts as a Novel Target for Ameliorating Sepsis-Induced Skeletal Muscle Atrophy in Mice Model. Shock. 2025. PMID: 40961379. doi:10.1097/SHK.0000000000002703
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。